You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 34.205.0.0/16 has been blocked (disabled) by ‪ST47‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider. To prevent abuse, web hosts may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a web host's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and they should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 05:44, 30 September 2026.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Jon Kolbert‬. The reason given is Open proxy/Webhost: See the help page if you are affected .
- Start of block: 05:38, 21 February 2024
- Expiry of block: 05:38, 21 February 2029
Your current IP address is 34.205.141.108. The blocked range is 34.205.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

{| class="wikitable <!--sortable--> mw-collapsible (({state<includeonly>|mw-collapsed</includeonly>))}" style="margin-left: auto; margin-right: auto; border: none;"
|+ class="nowrap" | ((Navbar|Pharmacodynamics of aromatase inhibitors|mini=y)) Pharmacodynamics of <noinclude>((No selflink|aromatase inhibitor))s</noinclude><includeonly>aromatase inhibitors</includeonly>
|-
! Generation !! Medication !! Dosage !! % inhibition<sup>a</sup> !! Class<sup>b</sup> !! ((Abbr|IC<sub>50</sub>|Half-maximal inhibitory concentration))<sup>c</sup>
|-
| rowspan="4" | First || rowspan="2" | ((No selflink|Testolactone)) || 250&nbsp;mg 4x/day ((abbr|p.o.|per os (oral))) || ? || rowspan="2" | Type I || rowspan="2" | ?
|-
| 100&nbsp;mg 3x/week ((abbr|i.m.|intramuscular injection)) || ?
|-
| ((No selflink|Rogletimide)) || 200&nbsp;mg 2x/day ((abbr|p.o.|per os (oral)))<br />400&nbsp;mg 2x/day ((abbr|p.o.|per os (oral)))<br />800&nbsp;mg 2x/day ((abbr|p.o.|per os (oral))) || 50.6%<br />63.5%<br />73.8% || Type II || ?
|-
| ((No selflink|Aminoglutethimide)) || 250 mg&nbsp;mg 4x/day ((abbr|p.o.|per os (oral))) || 90.6% || Type II || 4,500&nbsp;nM
|-
| rowspan="3" | Second || rowspan="2" | ((No selflink|Formestane)) || 125&nbsp;mg 1x/day ((abbr|p.o.|per os (oral)))<br />125&nbsp;mg 2x/day ((abbr|p.o.|per os (oral)))<br />250&nbsp;mg 1x/day ((abbr|p.o.|per os (oral))) || 72.3%<br />70.0%<br />57.3% || rowspan="2" | Type I || rowspan="2" | 30&nbsp;nM
|-
| 250&nbsp;mg 1x/2&nbsp;weeks ((abbr|i.m.|intramuscular injection))<br />500&nbsp;mg 1x/2&nbsp;weeks ((abbr|i.m.|intramuscular injection))<br />500&nbsp;mg 1x/1&nbsp;week ((abbr|i.m.|intramuscular injection)) || 84.8%<br />91.9%<br />92.5%
|-
| ((No selflink|Fadrozole)) || 1&nbsp;mg 1x/day ((abbr|p.o.|per os (oral)))<br />2&nbsp;mg 2x/day ((abbr|p.o.|per os (oral))) || 82.4%<br />92.6% || Type II || ?
|-
| rowspan="3" | Third || ((No selflink|Exemestane)) || 25&nbsp;mg 1x/day ((abbr|p.o.|per os (oral))) || 97.9% || Type I || 15&nbsp;nM
|-
| ((No selflink|Anastrozole)) || 1&nbsp;mg 1x/day ((abbr|p.o.|per os (oral)))<br />10&nbsp;mg 1x/day ((abbr|p.o.|per os (oral))) || 96.7–97.3%<br />98.1% || Type II || 10&nbsp;nM
|-
| ((No selflink|Letrozole)) || 0.5&nbsp;mg 1x/day ((abbr|p.o.|per os (oral)))<br />2.5&nbsp;mg 1x/day ((abbr|p.o.|per os (oral))) || 98.4%<br />98.9%–>99.1% || Type II || 2.5&nbsp;nM
|- class="sortbottom"
| colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Footnotes:''' <sup>a</sup> = In [[postmenopause|postmenopausal]] women. <sup>b</sup> = Type I: [[Steroidal]], [[irreversible inhibitor|irreversible]] ([[active site|substrate-binding site]]). Type II: [[Nonsteroidal]], [[reversible inhibitor|reversible]] (binding to and interference with the [[cytochrome P450]] [[heme]] [[moiety (chemistry)|moiety]]). <sup>c</sup> = In [[breast cancer]] [[homogenate]]s. '''Sources:''' <noinclude><ref name="pmid14513434">((cite journal | vauthors = Lønning P, Pfister C, Martoni A, Zamagni C | title = Pharmacokinetics of third-generation aromatase inhibitors | journal = Semin. Oncol. | volume = 30 | issue = 4 Suppl 14 | pages = 23–32 | date = August 2003 | pmid = 14513434 | doi = 10.1016/S0093-7754(03)00305-1 ))</ref><ref name="pmid14513432">((cite journal | vauthors = Miller WR | title = Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer | journal = Semin. Oncol. | volume = 30 | issue = 4 Suppl 14 | pages = 3–11 | date = August 2003 | pmid = 14513432 | doi = 10.1016/S0093-7754(03)00302-6 ))</ref><ref name="pmid11060785">((cite journal | vauthors = Lønning PE | title = Pharmacology and clinical experience with exemestane | journal = Expert Opin Investig Drugs | volume = 9 | issue = 8 | pages = 1897–905 | date = August 2000 | pmid = 11060785 | doi = 10.1517/13543784.9.8.1897 ))</ref><ref name="Geisler2005">((cite journal|last1=Geisler|first1=J.|title=Aromatase Inhibition: Translation into a Successful Therapeutic Approach|journal=Clinical Cancer Research|volume=11|issue=8|year=2005|pages=2809–2821|issn=1078-0432|doi=10.1158/1078-0432.CCR-04-2187))</ref><ref name="Lønning2001">((cite journal|last1=Lønning|first1=P.E.|title=Exemestane: a review of its clinical efficacy and safety|journal=The Breast|volume=10|issue=3|year=2001|pages=198–208|issn=09609776|doi=10.1054/brst.2001.0293))</ref></noinclude><includeonly>See template.</includeonly>
|}<!--

--><noinclude>((Documentation|content=
==References==
((Reflist))
))
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>

Pages transcluded onto the current version of this page (help):

Aminoglutethimide (edit)
Anastrozole (edit)
Aromatase inhibitor (edit)
Exemestane (edit)
Fadrozole (edit)
Formestane (edit)
Letrozole (edit)
Rogletimide (edit)
Testolactone (edit)
Template:Abbr (view source) (protected)
Template:Cite journal (view source) (protected)
Template:Documentation (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:Navbar (view source) (protected)
Template:No self link (view source) (semi-protected)
Template:No selflink (view source) (semi-protected)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Module:Arguments (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Redirect (view source) (protected)
Module:String (view source) (protected)

Return to Template:Pharmacodynamics of aromatase inhibitors.

Retrieved from "https://en.wikipedia.org/wiki/Template:Pharmacodynamics_of_aromatase_inhibitors"